BR112017015353A2 - inalador de pó seco que compreende propionato de fruticasona e xinafoato de salmeterol - Google Patents
inalador de pó seco que compreende propionato de fruticasona e xinafoato de salmeterolInfo
- Publication number
- BR112017015353A2 BR112017015353A2 BR112017015353A BR112017015353A BR112017015353A2 BR 112017015353 A2 BR112017015353 A2 BR 112017015353A2 BR 112017015353 A BR112017015353 A BR 112017015353A BR 112017015353 A BR112017015353 A BR 112017015353A BR 112017015353 A2 BR112017015353 A2 BR 112017015353A2
- Authority
- BR
- Brazil
- Prior art keywords
- fruticasone
- propionate
- dose
- dry powder
- salmeterol xinafoate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
- A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
- A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção refere-se a um inalador de pó seco que compreende: um medicamento em pó seco que compreende propionato de fruticasona, xinafoato de salmeterol e um veículo de lactose; em que a dose entregue de propionato de fruticasona por atuação é menor do que 100 µg; e em que a dose proporciona um fev1 linha base ajustada em u paciente maior do que 150ml dentro de 30 minutos de recebimento da dose. um método para tratamento de um paciente inclui administrar em um paciente um medicamento em pó seco que possui propionato de fruticasona, xinafoato de salmeterol e um veículo de lactose; em que a dose entregue de propionato de fruticasona por atuação é de menos de 100 µg; e em que a dose proporciona uma fev1 linha base-ajustada em um paciente de mais de 150ml dentro de 30 minutos de recebimento da dose.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105479P | 2015-01-20 | 2015-01-20 | |
| PCT/US2016/014072 WO2016118589A1 (en) | 2015-01-20 | 2016-01-20 | Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017015353A2 true BR112017015353A2 (pt) | 2018-01-16 |
Family
ID=55443303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017015353A BR112017015353A2 (pt) | 2015-01-20 | 2016-01-20 | inalador de pó seco que compreende propionato de fruticasona e xinafoato de salmeterol |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20180015035A1 (pt) |
| EP (1) | EP3247331A1 (pt) |
| JP (1) | JP2018503687A (pt) |
| KR (1) | KR20170103975A (pt) |
| CN (1) | CN107530357A (pt) |
| AR (1) | AR104771A1 (pt) |
| AU (2) | AU2016209363B2 (pt) |
| BR (1) | BR112017015353A2 (pt) |
| CA (1) | CA2974125A1 (pt) |
| CL (1) | CL2017001859A1 (pt) |
| CO (1) | CO2017008395A2 (pt) |
| EA (1) | EA201791632A1 (pt) |
| HK (1) | HK1245125A1 (pt) |
| IL (1) | IL253499A0 (pt) |
| MA (1) | MA41378A (pt) |
| MX (2) | MX2017009122A (pt) |
| PE (1) | PE20171258A1 (pt) |
| TW (1) | TW201628607A (pt) |
| WO (1) | WO2016118589A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016007771B1 (pt) * | 2013-10-07 | 2023-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Inalador de pó seco e uso de propionato de fluticasona e salmeterol |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| US11344685B2 (en) * | 2016-11-18 | 2022-05-31 | Norton (Waterford) Limited | Drug delivery device with electronics |
| CN110201281B (zh) * | 2018-02-28 | 2021-08-06 | 张江 | 吸入给药装置和吸入给药组合结构 |
| CN110201278B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药的药盒和吸入给药组合结构 |
| CN110201280B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药装置的吸嘴和吸入给药装置 |
| CN110064110A (zh) * | 2019-05-29 | 2019-07-30 | 上海理工大学 | 一种容积旋钮式干粉储存吸入装置 |
| GB2585206B (en) * | 2019-07-01 | 2021-08-11 | Merxin Ltd | Portable inhaler |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| PE20020163A1 (es) * | 2000-06-23 | 2002-03-04 | Norton Healthcare Ltd | Sistema presurizado de receptaculo para inhalador de medicamento |
| TWI224511B (en) * | 2000-06-23 | 2004-12-01 | Norton Healthcare Ltd | De-agglomerator for breath-actuated dry powder inhaler |
| AR030516A1 (es) * | 2000-08-31 | 2003-08-20 | Glaxo Group Ltd | Uso de una combinacion de salmeterol y fluticasona |
| PT2283817T (pt) * | 2000-11-30 | 2016-08-22 | Vectura Ltd | Método de fabrico de partículas para utilização numa composição farmacêutica |
| GB0124523D0 (en) * | 2001-10-12 | 2001-12-05 | Glaxo Group Ltd | Pharmaceutical combination |
| EP1556018A1 (en) | 2002-09-30 | 2005-07-27 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
| US9114081B2 (en) * | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| TWI695723B (zh) * | 2009-05-29 | 2020-06-11 | 美商沛爾醫療股份有限公司 | 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統 |
| EP2477642A4 (en) * | 2009-09-17 | 2013-03-13 | Mutual Pharmaceutical Co | METHOD FOR THE TREATMENT OF ASTHMA WITH ANTIVIRUS AGENTS |
| GB0919465D0 (en) * | 2009-11-06 | 2009-12-23 | Norton Healthcare Ltd | Airflow adaptor for a breath-actuated dry powder inhaler |
| HUE026806T2 (en) * | 2010-05-18 | 2016-07-28 | Ivax Pharmaceuticals Ireland | Dose counter inhaler |
| US20130064870A1 (en) * | 2010-05-20 | 2013-03-14 | Sun Pharma Advanced Research Company Limited | Dry powder inhalation composition |
| KR20130140358A (ko) * | 2012-06-14 | 2013-12-24 | 한미약품 주식회사 | 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법 |
| CA2910697A1 (en) * | 2013-04-29 | 2014-11-06 | Sanofi Sa | Inhalable pharmaceutical compositions and the inhaler devices containing them |
| BR112016007771B1 (pt) | 2013-10-07 | 2023-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Inalador de pó seco e uso de propionato de fluticasona e salmeterol |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
-
2016
- 2016-01-19 MA MA041378A patent/MA41378A/fr unknown
- 2016-01-20 CA CA2974125A patent/CA2974125A1/en not_active Abandoned
- 2016-01-20 TW TW105101637A patent/TW201628607A/zh unknown
- 2016-01-20 EP EP16706919.4A patent/EP3247331A1/en not_active Withdrawn
- 2016-01-20 KR KR1020177023075A patent/KR20170103975A/ko not_active Application Discontinuation
- 2016-01-20 BR BR112017015353A patent/BR112017015353A2/pt not_active Application Discontinuation
- 2016-01-20 MX MX2017009122A patent/MX2017009122A/es unknown
- 2016-01-20 AR ARP160100136A patent/AR104771A1/es active IP Right Grant
- 2016-01-20 US US15/544,900 patent/US20180015035A1/en not_active Abandoned
- 2016-01-20 EA EA201791632A patent/EA201791632A1/ru unknown
- 2016-01-20 AU AU2016209363A patent/AU2016209363B2/en active Active
- 2016-01-20 US US15/001,853 patent/US9415008B2/en active Active
- 2016-01-20 JP JP2017556791A patent/JP2018503687A/ja active Pending
- 2016-01-20 CN CN201680011413.7A patent/CN107530357A/zh active Pending
- 2016-01-20 PE PE2017001234A patent/PE20171258A1/es unknown
- 2016-01-20 WO PCT/US2016/014072 patent/WO2016118589A1/en active Application Filing
-
2017
- 2017-07-12 MX MX2021006751A patent/MX2021006751A/es unknown
- 2017-07-16 IL IL253499A patent/IL253499A0/en unknown
- 2017-07-18 CL CL2017001859A patent/CL2017001859A1/es unknown
- 2017-08-17 CO CONC2017/0008395A patent/CO2017008395A2/es unknown
-
2018
- 2018-04-11 HK HK18104726.3A patent/HK1245125A1/zh unknown
-
2021
- 2021-05-04 AU AU2021202784A patent/AU2021202784A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021006751A (es) | 2021-07-15 |
| AU2016209363A1 (en) | 2017-08-24 |
| PE20171258A1 (es) | 2017-08-28 |
| US9415008B2 (en) | 2016-08-16 |
| AR104771A1 (es) | 2017-08-16 |
| CA2974125A1 (en) | 2016-07-28 |
| US20160206559A1 (en) | 2016-07-21 |
| CO2017008395A2 (es) | 2018-01-05 |
| CN107530357A (zh) | 2018-01-02 |
| MX2017009122A (es) | 2017-10-12 |
| JP2018503687A (ja) | 2018-02-08 |
| MA41378A (fr) | 2017-11-28 |
| KR20170103975A (ko) | 2017-09-13 |
| CL2017001859A1 (es) | 2018-04-06 |
| AU2016209363B2 (en) | 2021-02-04 |
| EP3247331A1 (en) | 2017-11-29 |
| EA201791632A1 (ru) | 2017-12-29 |
| AU2021202784A1 (en) | 2021-05-27 |
| HK1245125A1 (zh) | 2018-08-24 |
| TW201628607A (zh) | 2016-08-16 |
| US20180015035A1 (en) | 2018-01-18 |
| IL253499A0 (en) | 2017-09-28 |
| WO2016118589A1 (en) | 2016-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017015353A2 (pt) | inalador de pó seco que compreende propionato de fruticasona e xinafoato de salmeterol | |
| PH12016500619A1 (en) | Dry powder inhaler | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| BR112016001446A8 (pt) | composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida | |
| BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
| BR112012023407A2 (pt) | composição em pó farmacêutica para instalação, e, processo para a preparação da mesma. | |
| BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
| BR112018011266A2 (pt) | ?composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica? | |
| BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
| BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
| BR112015000321A2 (pt) | formulações de laquinimod sem agente alcalinizante | |
| AR100369A1 (es) | Composición de dosis fija de formoterol y budesonide | |
| BR112017022846A2 (pt) | combinação de dose fixa inviolável que proporciona rápida liberação de dois fármacos de partículas diferentes | |
| UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| BR112015029709A2 (pt) | dihidroetorfina para o fornecimento de alívio da dor e anestesia | |
| BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento | |
| BR112014009141A8 (pt) | regime de dosagem para um modulador ou agonista do receptor s1p | |
| BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
| BR112014030288A8 (pt) | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila | |
| BR112017022856A2 (pt) | combinação de dose fixa inviolável que proporciona rápida liberação de duas drogas a partir de partículas | |
| BR112018072177A2 (pt) | composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta | |
| MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
| BR112018003930A2 (pt) | regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo | |
| BR112017022855A2 (pt) | combinação de dose fixa inviolável que provê liberação rápida de dois fármacos a partir de partículas e um pó | |
| BR112018002433A2 (pt) | composição farmacêutica para tratamento da enxaqueca |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09S | Decision of refusal: publication cancelled [chapter 9.2.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 9.2 NA RPI NO 2749 DE 12/09/2023 POR TER SIDO INDEVIDA. |